Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2463-2468

  Sorensen, Boe S ^a   Mortensen, Lise S ^a   Andersen, Jørn ^a   Nexo, Ebba ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Breast cancer; HER2; Plasma DNA; Trastuzumab

Indexed keywords

DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; LOADING DRUG DOSE; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2;

EID: 77955060263     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG and Edwards J: Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 100: 680-683, 2009.
3. Pegram MD and Slamon DJ: Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26: 89-95, 1999.
4. Seidman AD, Former MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L and Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595, 2001.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
6. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Malimann P, Gelmon K, Wilcken N, Wist E, Sanchez RP and Piccart-Gebhart MJ: 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29-36, 2007. (Pubitemid 46039831)
7. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996.
8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
9. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R and Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664, 2000.
10. Bartlett J, Mallon E and Cooke T: The clinical evaluation of HER-2 status: which test to use? J Pathol 199: 411-417, 2003.
11. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D and Ghani F: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7: R436-R443, 2005.
12. Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C and Zielinski CC: Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618-1624, 2004. (Pubitemid 38435551)
13. Tsang JC and Lo YM: Circulating nucleic acids in plasma/serum. Pathology 39: 197-207, 2007.
14. Taback B, O'Day SJ, Boasberg PD, Shu S, Fournier P, Elashoff R, Wang HJ and Hoon DS: Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 96: 152-156, 2004.
15. Mehra N, Penning M, Maas J, van DN, Giles RH and Voest EE: Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res 13: 421-426, 2007. (Pubitemid 46225345)
16. Yung TK, Chan KC, Mok TS, Tong J, To KF and Lo YM: Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15: 2076-2084, 2009.
17. Frattini M, Gallino G, Signoroni S, Balestra D, Battaglia L, Sozzi G, Leo E, Pilotti S and Pierotti MA: Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci 1075: 185-190, 2006. (Pubitemid 44532783)
18. Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E and Hamilton-Dutoit S: Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn 6: 42-51, 2004. (Pubitemid 38208344)
19. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
20. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Aran B, Esmaeli B, Fritsche HA, Sneige N, Smith TL and Hortobagyi GN: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808, 2002.
21. Baselga J: Is circulating HER-2 more than just a tumor marker? Clin Cancer Res 7: 2605-2607, 2001.
22. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L and Hudis C: Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16: 234-239, 2005.
23. Schondorf T, Hoopmann M, Warm M, Neumann R, Thomas A, Gohring UJ, Eisberg C and Mallmann P: Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course. Clin Chem 48: 1360-1362, 2002.